Based on the BEXIMCO PHARMA.GDR REGS 1 stock forecast from 0 analysts, the average analyst target price for BEXIMCO PHARMA.GDR REGS 1 is not available over the next 12 months. BEXIMCO PHARMA.GDR REGS 1’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BEXIMCO PHARMA.GDR REGS 1 is Bullish , which is based on 6 positive signals and 2 negative signals. At the last closing, BEXIMCO PHARMA.GDR REGS 1’s stock price was EUR 0.42. BEXIMCO PHARMA.GDR REGS 1’s stock price has changed by +0.00% over the past week, -3.67% over the past month and +2.44% over the last year.
No recent analyst target price found for BEXIMCO PHARMA.GDR REGS 1
No recent average analyst rating found for BEXIMCO PHARMA.GDR REGS 1
Company Overview BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh. Read Less
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system,...Read More
Frequently Asked Questions About BEXIMCO PHARMA.GDR REGS 1 (R2WA:F) Stock
Stock Target Advisor's fundamental analysis for BEXIMCO PHARMA.GDR REGS 1's stock is Bullish .
R2WA:F stock's dividend yield is 6.55%.
Our analysis grades R2WA:F stock's dividend yield at A. This means that R2WA:F stock's dividend yield is above 93% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this R2WA:F may be a good dividend stock for its sector.
Unfortunately we do not have enough data on R2WA:F's stock to indicate what its average analyst target is.
R2WA:F stock's Price/Earning ratio is 5.00.
Our analysis grades R2WA:F stock's Price / Earning ratio at B. This means that R2WA:F stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this R2WA:F may be undervalued for its sector.
The last closing price of R2WA:F's stock was EUR 0.42.
The most recent market capitalization for R2WA:F is EUR 0.20B.
Unfortunately we do not have enough analyst data on R2WA:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BEXIMCO PHARMA.GDR REGS 1's stock.
As per our most recent records BEXIMCO PHARMA.GDR REGS 1 has 5,700 Employees.
BEXIMCO PHARMA.GDR REGS 1's registered address is 19 Dhanmondi R/A, Dhaka, Bangladesh, 1205.
You can get more information about it from BEXIMCO PHARMA.GDR REGS 1's website at https://www.beximcopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for R2WA:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
